ZA201500161B - Phosphoramidic acid prodrugs of 5-[-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine -3-sulfonamide - Google Patents

Phosphoramidic acid prodrugs of 5-[-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine -3-sulfonamide

Info

Publication number
ZA201500161B
ZA201500161B ZA2015/00161A ZA201500161A ZA201500161B ZA 201500161 B ZA201500161 B ZA 201500161B ZA 2015/00161 A ZA2015/00161 A ZA 2015/00161A ZA 201500161 A ZA201500161 A ZA 201500161A ZA 201500161 B ZA201500161 B ZA 201500161B
Authority
ZA
South Africa
Prior art keywords
ylmethylamino
quinazolin
sulfonamide
pyridin
pyridine
Prior art date
Application number
ZA2015/00161A
Other languages
English (en)
Inventor
Navnath Dnyanoba Yadav
Jayakumar S Warrier
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201500161B publication Critical patent/ZA201500161B/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509Six-membered rings
    • C07F9/6512Six-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65128Six-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA2015/00161A 2012-06-11 2015-01-09 Phosphoramidic acid prodrugs of 5-[-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine -3-sulfonamide ZA201500161B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261657913P 2012-06-11 2012-06-11
PCT/US2013/044882 WO2013188254A1 (en) 2012-06-11 2013-06-10 Phosphoramidic acid prodrugs of 5 - [5 - phenyl- 4 - (pyridin- 2 - ylmethylamino) quinazolin- 2 - yl] pyridine- 3 - sulfonamide

Publications (1)

Publication Number Publication Date
ZA201500161B true ZA201500161B (en) 2017-04-26

Family

ID=48670111

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2015/00161A ZA201500161B (en) 2012-06-11 2015-01-09 Phosphoramidic acid prodrugs of 5-[-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine -3-sulfonamide

Country Status (34)

Country Link
US (1) US9238666B2 (enExample)
EP (1) EP2858987B1 (enExample)
JP (1) JP6234450B2 (enExample)
KR (1) KR102092984B1 (enExample)
CN (1) CN104350048B (enExample)
AR (1) AR091402A1 (enExample)
AU (1) AU2013274619B2 (enExample)
BR (1) BR112014030629B1 (enExample)
CA (1) CA2876359C (enExample)
CL (1) CL2014003361A1 (enExample)
CO (1) CO7160032A2 (enExample)
CY (1) CY1120432T1 (enExample)
DK (1) DK2858987T3 (enExample)
EA (1) EA024692B1 (enExample)
ES (1) ES2675314T3 (enExample)
HR (1) HRP20180815T8 (enExample)
HU (1) HUE039210T2 (enExample)
IL (1) IL236074A (enExample)
LT (1) LT2858987T (enExample)
MX (1) MX356699B (enExample)
MY (1) MY169219A (enExample)
NZ (1) NZ703632A (enExample)
PE (1) PE20150228A1 (enExample)
PH (1) PH12014502747B1 (enExample)
PL (1) PL2858987T3 (enExample)
PT (1) PT2858987T (enExample)
RS (1) RS57376B1 (enExample)
SG (1) SG11201408076WA (enExample)
SI (1) SI2858987T1 (enExample)
SM (1) SMT201800369T1 (enExample)
TN (1) TN2014000499A1 (enExample)
TW (1) TWI571470B (enExample)
WO (1) WO2013188254A1 (enExample)
ZA (1) ZA201500161B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
US9403834B2 (en) * 2013-03-11 2016-08-02 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
JP6386527B2 (ja) * 2013-03-11 2018-09-05 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company カリウムイオンチャネル阻害剤としてのピロロピリダジン
SG11201803645PA (en) * 2015-11-19 2018-06-28 Biohaven Pharm Holding Co Ltd Amine prodrugs of pharmaceutical compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612359A (en) 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
GB9514380D0 (en) * 1995-07-13 1995-09-13 Knoll Ag Therapeutic agents
TW536540B (en) 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
NZ508118A (en) 1998-07-06 2003-07-25 Bristol Myers Squibb Co Heteroaryl substituted biphenyl sulfonamides useful as dual angiotensin endothelin receptor antogonists
ES2215474B1 (es) 2002-12-24 2005-12-16 J. URIACH & CIA S.A. Nuevos derivados de fosforamida.
AR049847A1 (es) 2004-07-29 2006-09-06 Merck & Co Inc Inhibidores de los canales de potasio
EP1838690A2 (en) * 2004-12-21 2007-10-03 Devgen N.V. Compounds with kv4 ion channel activity
TWI488851B (zh) * 2009-09-03 2015-06-21 必治妥美雅史谷比公司 作為鉀離子通道抑制劑之喹唑啉
EP2473054B1 (en) 2009-09-04 2017-06-14 The Regents of the University of Michigan Compositions and methods for treatment of leukemia
AR079814A1 (es) 2009-12-31 2012-02-22 Otsuka Pharma Co Ltd Compuestos heterociclicos, composiciones farmaceuticas que los contienen y sus usos
US8592427B2 (en) * 2010-06-24 2013-11-26 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
US9050345B2 (en) * 2013-03-11 2015-06-09 Bristol-Myers Squibb Company Pyrrolotriazines as potassium ion channel inhibitors
WO2014143609A1 (en) * 2013-03-11 2014-09-18 Bristol-Myers Squibb Company Isoquinolines as potassium ion channel inhibitors
US9242966B2 (en) * 2013-03-11 2016-01-26 Bristol-Myers Squibb Company Phthalazines as potassium ion channel inhibitors

Also Published As

Publication number Publication date
TN2014000499A1 (en) 2016-03-30
NZ703632A (en) 2016-01-29
BR112014030629B1 (pt) 2021-12-21
TWI571470B (zh) 2017-02-21
KR20150023667A (ko) 2015-03-05
HK1203928A1 (en) 2015-11-06
PT2858987T (pt) 2018-07-04
JP2015521598A (ja) 2015-07-30
PE20150228A1 (es) 2015-02-19
EP2858987B1 (en) 2018-04-25
MY169219A (en) 2019-03-19
EA024692B1 (ru) 2016-10-31
PL2858987T3 (pl) 2018-08-31
EP2858987A1 (en) 2015-04-15
SI2858987T1 (en) 2018-06-29
RS57376B1 (sr) 2018-08-31
MX2014014525A (es) 2015-02-24
ES2675314T3 (es) 2018-07-10
KR102092984B1 (ko) 2020-03-24
HRP20180815T8 (hr) 2019-02-08
CA2876359C (en) 2020-01-21
JP6234450B2 (ja) 2017-11-22
AR091402A1 (es) 2015-02-04
AU2013274619A1 (en) 2015-01-29
MX356699B (es) 2018-06-11
CL2014003361A1 (es) 2015-05-29
CA2876359A1 (en) 2013-12-19
CY1120432T1 (el) 2019-07-10
CN104350048A (zh) 2015-02-11
US20150175641A1 (en) 2015-06-25
WO2013188254A1 (en) 2013-12-19
TW201402592A (zh) 2014-01-16
HRP20180815T1 (hr) 2018-06-29
US9238666B2 (en) 2016-01-19
IL236074A (en) 2016-08-31
SG11201408076WA (en) 2015-01-29
CO7160032A2 (es) 2015-01-15
HUE039210T2 (hu) 2018-12-28
BR112014030629A2 (pt) 2017-06-27
PH12014502747A1 (en) 2015-02-02
AU2013274619B2 (en) 2017-09-28
SMT201800369T1 (it) 2018-09-13
EA201492256A1 (ru) 2016-05-31
LT2858987T (lt) 2018-07-10
IL236074A0 (en) 2015-02-01
PH12014502747B1 (en) 2015-02-02
DK2858987T3 (en) 2018-07-30
CN104350048B (zh) 2016-12-07

Similar Documents

Publication Publication Date Title
ZA201501847B (en) Formulations of enzalutamide
PL2819982T3 (pl) Proleki witaminy k
AP4063A (en) Dimethyl-benzoic acid compounds
IL235856B (en) Daggerlix production
PL2934134T3 (pl) Zastosowania inhalacji kwasem acetylosalicylowym
ZA201408857B (en) Prodrug of fluorine-containing amino acid
ZA201500161B (en) Phosphoramidic acid prodrugs of 5-[-phenyl-4-(pyridin-2-ylmethylamino)quinazolin-2-yl]pyridine -3-sulfonamide
ZA201500488B (en) Manufacture of wheels
GB201204590D0 (en) Prodrugs of thiazolamine compounds
GB2505968B (en) Manufacturing of metal bipolar plates
IL218233A0 (en) Manufacturing phosphoric acid
GB201204587D0 (en) Prodrugs of guanidine compounds
GB201204589D0 (en) Prodrugs of guanidine compounds
GB201212395D0 (en) A set of connectors
GB201116822D0 (en) Jack of all trades
GB201207606D0 (en) Prodrugs